AIM ImmunoTech Inc. (AIM) stock prices were down by 1.42% as of the market closing on May 28th, 2021, bringing the price per share down to USD$2.08 at the end of the trading day. Subsequent pre-market fluctuations have seen the stock fall by 2.40%, bringing it down to USD$2.03.
Extension of Agreement with Smoore
May 27th, 2021 saw the company announce the extension of its Material Transfer and Research Agreement with Shenzhen Smoore Technology Ltd by two years. The collaboration with the subsidiary of Smoore International Holdings Ltd aims to develop Ampligen as a potential inhalation therapy for Covid-19 and other respiratory viral diseases. The agreement was entered into by AIM on April 1st, 2020, with the aim of studying the utilization of a new Smoore inhalation delivery device and Ampligen as a prospective treatment approach for the coronavirus pandemic.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Read More
Ampligen Development
Concurrently, the past year has seen the company focus on the development of a personal inhalation device designed to administer Ampligen, given temperature parameters of dsRNA. More recently, AIM has used an ex vivo 3D model in primary human respiratory epithelial cells at Utah State University to study the safety and efficacy of Ampligen. The study showed Ampligen as being able to lower Covid-19 infectious viral yields by 90% at clinically viable intranasal Ampligen dosage levels. Having conducted relevant intranasal safety testing, AIM forecasts commencing inhalation safety testing before the end of 2021.
Scope of Ampligen
On account of the readiness for the development of the concept or an Ampligen inhalation delivery device and the company’s track record of high safety and efficacy, AIM is pushing for the further development and commercialization of Ampligen. With the world hurtling towards global immunizations, the company hopes to address a portion of that market and for Ampligen to also treat other respiratory viral diseases that will have a scope beyond the pandemic. The company is currently in the process of planning a Phase 1/1 inhalation clinical study that will operate in tandem with Smoore’s device development testing.
Partnership Merits
One of the Smoore’s focal points for research and development is the application of vaping technology in healthcare and pharmaceutical fields. Their collaboration with AIM will explore applications of advanced atomization technology in relation to medical inhalation therapy. Smoore will coordinate its device development efforts in conjunction with AIM’s plan and the regulation needs to move into next phase testing on schedule.
Future Outlook for AIM
With the extension of the collaboration with Smoore, AIM has consolidated a potentially prosperous several quarter ahead of it. The company is poised to capitalize on the joint efforts of the parties involved to facilitate further growth. Current and potential investors are hopeful that the company will manage to leverage the resources at their disposal to usher in significant and sustained increases in shareholder value.
